Back to Search Start Over

Efficacy of beta-lactam/beta-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project)

Authors :
Pierrotti, Ligia C.
Perez-Nadales, Elena
Fernandez-Ruiz, Mario
Gutierrez-Gutierrez, Belen
Hock Tan, Ban
Carratala, Jordi
Oriol, Isabel
Paul, Mical
Cohen-Sinai, Noa
Lopez-Medrano, Francisco
San-Juan, Rafael
Montejo, Miguel
Freire, Maristela P.
Cordero, Elisa
David, Miruna D.
Merino, Esperanza
Mehta Steinke, Seema
Grossi, Paolo A.
Cano, Angela
Seminari, Elena M.
Valerio, Maricela
Gunseren, Filiz
Rana, Meenakshi
Mularoni, Alessandra
Martin-Davila, Pilar
van Delden, Christian
Hamiyet Demirkaya, Melike
Kocak Tufan, Zeliha
Loeches, Belen
Iyer, Ranganathan N.
Soldani, Fabio
Eriksson, Britt-Marie
Pilmis, Benoit
Rizzi, Marco
Coussement, Julien
Clemente, Wanessa T.
Roilides, Emmanuel
Pascual, Alvaro
Martinez-Martinez, Luis
Rodriguez-Bano, Jesus
Torre-Cisneros, Julian
Maria Aguado, Jose
Pierrotti, Ligia C.
Perez-Nadales, Elena
Fernandez-Ruiz, Mario
Gutierrez-Gutierrez, Belen
Hock Tan, Ban
Carratala, Jordi
Oriol, Isabel
Paul, Mical
Cohen-Sinai, Noa
Lopez-Medrano, Francisco
San-Juan, Rafael
Montejo, Miguel
Freire, Maristela P.
Cordero, Elisa
David, Miruna D.
Merino, Esperanza
Mehta Steinke, Seema
Grossi, Paolo A.
Cano, Angela
Seminari, Elena M.
Valerio, Maricela
Gunseren, Filiz
Rana, Meenakshi
Mularoni, Alessandra
Martin-Davila, Pilar
van Delden, Christian
Hamiyet Demirkaya, Melike
Kocak Tufan, Zeliha
Loeches, Belen
Iyer, Ranganathan N.
Soldani, Fabio
Eriksson, Britt-Marie
Pilmis, Benoit
Rizzi, Marco
Coussement, Julien
Clemente, Wanessa T.
Roilides, Emmanuel
Pascual, Alvaro
Martinez-Martinez, Luis
Rodriguez-Bano, Jesus
Torre-Cisneros, Julian
Maria Aguado, Jose
Publication Year :
2021

Abstract

Background Whether active therapy with beta-lactam/beta-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTRs) remains unclear. Methods We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any cause) at days 7 and 30 from ESBL-E BSI onset was the primary and secondary study outcomes, respectively. Results Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 1.35-2.17), and lymphocyte count <= 500 cells/mu L at presentation (aOR: 3.16; 95% CI: 1.42-7.06) predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) was the most frequent active therapy, followed by BLBLI monotherapy (10.8%, mostly piperacillin-tazobactam). Propensity score (PS)-adjusted models revealed no significant impact of the choice of active therapy (carbapenem-containing vs any other regimen, BLBLI- vs carbapenem-based monotherapy) within the first 72 hours on any of the study outcomes. Conclusions Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov identifier: NCT02852902).

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1280665458
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1111.tid.13520